1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Endometrial Cancer-Pipeline Insights, 2017

Endometrial Cancer-Pipeline Insights, 2017

  • January 2017
  • -
  • Delve Insight


DelveInsight’s, “ Endometrial Cancer-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Endometrial Cancer. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Endometrial Cancer. DelveInsight’s Report also assesses the Endometrial Cancer therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope

- The report provides competitivepipeline landscape of Endometrial Cancer
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Endometrial Cancer pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Endometrial Cancer and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Table Of Contents

Endometrial Cancer-Pipeline Insights, 2017
Illustrative

- Endometrial Cancer Overview
- Endometrial Cancer Pipeline Therapeutics
- Endometrial Cancer Therapeutics under Development by Companies
- Endometrial Cancer Filed and Phase III Products
- Comparative Analysis
- Endometrial Cancer Phase II Products
- Comparative Analysis
- Endometrial Cancer Phase I and IND Filed Products
- Comparative Analysis
- Endometrial Cancer Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Endometrial Cancer - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Endometrial Cancer - Discontinued Products
- Endometrial Cancer - Dormant Products
- Companies Involved in Therapeutics Development for Endometrial Cancer
- Appendix
- Methodology
- Contact Us
- Disclaimer


List of Tables

- Number of Products under Development for Endometrial Cancer, 2017
- Number of Products under Development by Companies
- Comparative Analysis by Filed and Phase III Products, 2017
- Comparative Analysis Phase II Products, 2017
- Comparative Analysis Phase I and IND Filed Products, 2017
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2017
- Drug Candidates Profiles
- Endometrial Cancer Assessment by Monotherapy Products
- Endometrial Cancer Assessment by Combination Products
- Endometrial Cancer Assessment by Route of Administration
- Endometrial Cancer Assessment by Stage and Route of Administration
- Endometrial Cancer Assessment by Molecule Type
- Endometrial Cancer Assessment by Stage and Molecule Type
- Endometrial Cancer Therapeutics - Discontinued Products
- Endometrial Cancer Therapeutics - Dormant Products
- Products under Development by Companies, 2017


List of Figures

- Number of Products under Development for Endometrial Cancer, 2017
- Filed and Phase III Products, 2017
- Phase II Products, 2017
- Phase I and IND Filed Products, 2017
- Discovery and Pre-Clinical Stage Products, 2017
- Endometrial Cancer Assessment by Monotherapy Products
- Endometrial Cancer Assessment by Combination Products
- Endometrial Cancer Assessment by Route of Administration
- Endometrial Cancer Assessment by Stage and Route of Administration
- Endometrial Cancer Assessment by Molecule Type
- Endometrial Cancer Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Endometrial Cancer - Market Insights, Epidemiology and Market Forecast-2023

Endometrial Cancer - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • March 2017
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Endometrial Cancer - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and ...

Endometrial Cancer - Epidemiology Forecast To 2023

Endometrial Cancer - Epidemiology Forecast To 2023

  • $ 2750
  • Industry report
  • January 2017
  • by Delve Insight

DelveInsight “Endometrial Cancer - Epidemiology Forecast To 2023” provides an overview of the epidemiology trends of Endometrial Cancer in seven major markets (US, France, Germany, Italy, Spain, UK ...

Doxorubicin Market By Application (Ovarian, Multiple Myeloma, Kaposi Sarcoma, Leukemia, Bone Sarcoma, Breast, Endometrial, Gastric, Liver, Kidney, Other Cancers) And Segment Forecasts, 2013 - 2024

Doxorubicin Market By Application (Ovarian, Multiple Myeloma, Kaposi Sarcoma, Leukemia, Bone Sarcoma, Breast, Endometrial, Gastric, Liver, Kidney, Other Cancers) And Segment Forecasts, 2013 - 2024

  • $ 4950
  • Industry report
  • November 2016
  • by Grand View Research

The global doxorubicin market was valued at USD 0.81 billion in 2015 and is expected to reach a value of USD 1.38 billion by 2024, according to a new report by Grand View Research, Inc. The growing numbe ...


Download Unlimited Documents from Trusted Public Sources

Colorectal Cancer Statistics in the Netherlands

  • March 2017
    6 pages
  • Colorectal Canc...  

    Oncology  

  • Netherlands  

    Europe  

View report >

Breast Cancer Statistics in the US

  • March 2017
    26 pages
  • Breast Cancer  

    Genetic  

  • United States  

View report >

Colorectal Cancer Statistics and Sexually Transmitted Disease Statistics in the US

  • March 2017
    4 pages
  • Colorectal Canc...  

    Cancer  

    Sexually Transm...  

  • United States  

View report >

Related Market Segments :

Endometrial Cancer

ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.